National Cancer Institute (NCI) - Recruiting 18 years or older. - A Phase III Randomized, Double-Blind Trial of Chemoembolization With or Without Sorafenib in Unresectable Hepatocellular Carcinoma (HCC) in Patients With and Without Vascular Invasion.
sorafenib tosylate; placebo; doxorubicin hydrochloride; doxorubicin-eluting beads; cisplatin; mitomycin C
BTG International Inc. - Recruiting 18 years or older. - A Phase III Clinical Trial Evaluating TheraSpherer in Patients With Metastatic Colorectal Carcinoma of the Liver Who Have Failed First Line Chemotherapy.
Northwestern University - Recruiting 18 years or older. - An Investigator Initiated Multicenter Prospective Randomized Study of Chemoembolization Versus Radioembolization for the Treatment of Hepatocellular Carcinoma (PREMIERE Trial).
yttrium Y 90 glass microspheres; Cisplatin; Mitomycin; Doxorubicin
Baylor Research Institute - Recruiting 18 years or older. - A 36 Month Multi-center, Open Label, Randomized, Comparator Study to Evaluate the Efficacy and Safety of Everolimus Immunosuppression Treatment in Liver Transplantation for Hepatocellular Carcinoma Exceeding Milan Criteria.
Odense University Hospital - Recruiting 18 years or older. - The Value of Laparoscopic Ultrasound in Patients Undergoing Laparoscopic Resection for Cancer of the Colon or Rectum: A Prospective Randomized Trial.
Sun Yat-sen University - Recruiting 18 years to 75 years. - A Phase II Study to Evaluate the Surgical Conversion Rate in Patients Receiving FOLFOXIRI +/- Cetuximab for Unresectable Wild-Type KRAS/NRAS Colorectal Cancer With Metastases Confined to the Liver.
Provectus Pharmaceuticals - Recruiting 18 years or older. - A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics of PV-10 Chemoablation of Cancer Metastatic to the Liver or Hepatocellular Carcinoma Not Amenable to Resection or Transplant.
Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older. - Collection of Tissue, Blood and Other Specimens From Patients With Benign and Malignant Tumors of the Soft Tissue, Gastrointestinal Tract, and Other Intra-abdominal Sites..
M.D. Anderson Cancer Center - Recruiting 18 years or older. - A Phase I Clinical Trial of Hepatic Arterial Infusion of Oxaliplatin, Oral Capecitabine, With or Without Systemic Bevacizumab for Patients With Advanced Cancer Metastatic to the Liver.
National Cancer Institute (NCI) - Recruiting 18 years or older. - Phase I Pharmacokinetic Study of Dasatinib (BMS-354825) (NSC-732517; IND-73969) in Patients With Advanced Malignancies and Varying Levels of Liver Dysfunction.
National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older. - A Pilot Study of Tremelimumab, A Monoclonal Antibody Against CTLA-4, in Combination With Either Trans-Arterial Catheter Chemoembolization (TACE) or Radiofrequency Ablation (RFA) in Subjects With Hepatocellular Carcinoma (HCC).
Bayer - Recruiting 18 years or older. - A Randomized, Double-blind, Placebo-controlled Phase-III Study of Adjuvant Regorafenib Versus Placebo for Patients With Stage IV Colorectal Cancer After Curative Treatment of Liver Metastases.
M.D. Anderson Cancer Center - Recruiting 18 years or older. - Randomized Controlled Trial of Postoperative Thoracic Epidural Analgesia Versus Intravenous Patient Controlled Analgesia (3:1) in Patients Undergoing Liver and/or Pancreatic Resection.
BTG International Inc. - Recruiting 18 years or older. - A Prospective Randomized Clinical Trial on 90Yttrium Trans-arterial Radio-Embolization (TheraSpherer) vs. Standard of Care (Sorafenib) for the Treatment of Advanced Hepatocellular Carcinoma (HCC) With Portal Vein Thrombosis (PVT).
Northwestern University - Recruiting 18 years or older. - Dose Escalating Study of Yttrium 90 Microspheres (TheraSphere) With Capecitabine (Xeloda) for Intrahepatic Cholangiocarcinoma or Metastatic Disease to the Liver.
Hoffmann-La Roche - Recruiting 18 years to 75 years. - A Multi-center, Single-arm, Pilot Study of 5-FU Based Doublet Chemotherapy Plus Bevacizumab as Neoadjuvant Therapy for Patients With Previously Untreated Unresectable Liver-only Metastases From Colorectal Cancer.
bevacizumab [Avastin]; 5-FU based doublet chemotherapy
Northwest Biotherapeutics - Recruiting 18 years to 75 years. - A PHASE I/II CLINICAL TRIAL EVALUATING DCVax-Direct, AUTOLOGOUS ACTIVATED DENDRITIC CELLS FOR INTRATUMORAL INJECTION, IN PATIENTS WITH SOLID TUMORS.
European Organisation for Research and Treatment of Cancer - EORTC - Recruiting 18 years to 75 years. - Randomized Phase II Trial Evaluating the Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab as Perioperative Treatment in Patients With Resectable Liver Metastases From Wild Type KRAS Colorectal Cancer.
Hoffmann-La Roche - Recruiting 18 years or older. - A Multi-center, Open-label Clinical Trial to Evaluate the Objective Response Rate of Bevacizumab in Combination With Modified FOLFOX-6 Followed by One Year of Maintenance With Bevacizumab Alone in Patients With Initially Not or Borderline Resectable Colorectal Liver Metastases (The CLMO-001 Trial).
Hoffmann-La Roche - Recruiting 18 years or older. - A PHASE Ib, OPEN-LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ONARTUZUMAB GIVEN AS A SINGLE AGENT AND IN COMBINATION WITH SORAFENIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC).
National Cancer Institute (NCI) - Recruiting 18 years or older. - A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients With, Lymphomas, Chronic Lymphocytic Leukemia and Select Solid Tumors and Varying Degrees of Liver Dysfunction.
Pfizer - Recruiting 18 years or older. - A Phase 2, Randomized, Open Label Study To Evaluate The Efficacy, Safety, Pharmacodynamics, Pharmacokinetics Of The Anti-ALK-1 MAB PF-03446962 In Combination With Best Supportive Care VS. Best Supportive Care Alone In Adult Patients With Advanced Hepatocellular Carcinoma.
PF-03446962; Best Supportive Care; Best supportive care
Swiss Group for Clinical Cancer Research - Recruiting 18 years or older. - A Phase I Open Label/Phase II Randomized, Double-Blind, Multicenter Trial Investigating the Combination of Everolimus and TransArterial ChemoEmbolization (TACE) With Doxorubicin in Patients With Hepatocellular Carcinoma.
Technische Universitt Dresden - Recruiting 18 years or older. - Open, Randomized, Multicenter Phase II Trial With Cetuximab /5-FU/FA/Irinotecan or Cetuximab/5-FU/FA /Irinotecan/Oxaliplatin in K-ras/B-raf Wild Type Patients or With Irinotecan/Oxaliplatin/5-FU/FA With or Without Bevacizumab in K-ras Mutant Patients as Neoadjuvant Treatment in Patients With Non- Resectable Colorectal Liver Metastases..
M.D. Anderson Cancer Center - Recruiting N/A or older. - A Multi-arm Phase I Trial of Hepatic Arterial Infusion of Irinotecan With 1) Systemic Bevacizumab 2) Systemic Bevacizumab and Oxaliplatin 3) Systemic Bevacizumab and Cetuximab in Patients With Advanced Cancers Metastatic to the Liver.
Foundation for Liver Research - Recruiting 18 years or older. - A Randomized Comparison of a Fully Covered Self Expandable Metal Stent Versus a Partially Covered Self Expandable Metal Stent in Malignant Esophageal Strictures.
Kyowa Hakko Kirin Company, Limited - Recruiting 20 years or older. - A Phase III Randomized Double-blind, Placebo-controlled Trial of ARQ 197 in Subjects With c-MET Diagnostic-high Inoperable Hepatocellular Carcinoma (HCC) Treated With One Prior Sorafenib Therapy.
National Cancer Institute, Naples - Recruiting 18 years or older. - Sorafenib in the First Line Treatment of Advanced Hepatocellular Carcinoma With Child-Pugh Liver Function Class B: Multicentre Phase 3 Randomized Trial.
Seoul National University Hospital - Recruiting 18 years to 75 years. - Multicenter Prospective Randomized Phase II/III Study of Neoadjuvant Chemoradiation With Gemcitabine in Patients With Borderline Resectable Pancreatic Cancer.
National Cancer Institute (NCI) - Recruiting 18 years or older. - A Phase II Multi-Institutional Efficacy and Safety Study of Chemotherapy With Selective Internal Radiation Treatment Using Y-90 Microspheres (CHEMO-SIRT) in Patients With Colorectal Cancer Liver Metastasis.
Providence Health & Services - Recruiting 18 years or older. - Phase I/II Study of Stereotactic Body Radiation Therapy to Metastatic Lesions in the Liver or Lung in Combination With Monoclonal Antibody to OX40 in Patients With Progressive Metastatic Breast Cancer After Systemic Therapy..
National Cancer Institute (NCI) - Recruiting 2 years to 30 years. - A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (IND# 69896) in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma.
Masonic Cancer Center, University of Minnesota - Recruiting 18 years or older. - Prospective Study Comparing Lipiodol Plus Ethanol Solution Compared With Drug-Eluting Beads for Trans-arterial Chemoembolization of Liver in Treatment of Hepatocellular Carcinoma.
Drug-Eluting Beads (DEB) with Doxorubicin; Lipiodol Ethanol Mixture (LEM)
Masonic Cancer Center, University of Minnesota - Recruiting 18 years or older. - A Phase 1 Study of an IL-2 Expressing, Attenuated Salmonella Typhimurium in Patients With Unresectable Hepatic Spread From Any Non-Hematologic Primary.
Centre Hospitalier Universitaire, Amiens - Recruiting 18 years or older. - Associating Liver Partition and Portal Vein Ligation (ALPPS) for Potentially Resectable Liver Metastasis From Colorectal Cancer: Prospective Evaluation of the Early Two-stage Hepatectomy by the Simon's Methods.
Medical University of South Carolina - Recruiting 18 years or older. - A Randomized Open-Label Multi-Institution Phase II Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC).
Merck KGaA - Recruiting 18 years or older. - A Phase I, Open-label, Dose-escalation Study to Investigate the Safety, Tolerability, PD and PK of EMD 525797 Using DCE-MRI as a PK Measure of Response in Colorectal and Ovarian Cancer Patients With Liver Metastases After Failure of Standard Therapy.
Southwest Hospital, China - Recruiting 18 years to 75 years. - Treatment of Hepatocellular Carcinoma With Radiofrequency Ablation Associated With Postoperative Transhepatic Arterial Chemoembolization--a Prospective Randomized Clinical Trial.
radiofrequency ablation associated with TACE; radiofrequency ablation only
Asan Medical Center - Recruiting 20 years to 75 years. - Randomized Phase II Trial of Preoperative Chemoradiation With or Without Induction Chemotherapy In Patients With Locally Advanced Or Borderlinely Resectable Rectal Cancer With Resectable Synchronous Liver Metastases.
Gachon University Gil Medical Center - Recruiting 18 years to 80 years. - Prospective Phase II Trial on Prophylactic Perihepatic Lymphadenectomy in Patients With Colorectal Cancer With Liver Metastasis.
National Cancer Institute (NCI) - Recruiting 18 years or older. - Randomized Phase II-III Study of Chemoradiation With Fluorouracil and Cisplatin Versus Chemotherapy (Gemcitabine/Oxaliplatin) in Non Resectable But Non Metastatic Cancer of the Biliary Tract.
Medstar Research Institute - Recruiting 9 years to 17 years. - Immunogenicity Of A Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, And 18) L1 Virus-Like Particle Vaccine In Male And Female Adolescent Transplant Recipients..
Peking Union Medical College Hospital - Recruiting 18 years to 90 years. - A Clinical Study to Evaluate the Clinical Outcomes of Hepatectomy With Nutritional Risk After Preoperative Nutritional Support.
Hospital Authority, Hong Kong - Recruiting 18 years or older. - A Comparative Study of the Efficacy of Transcatheter Arterial Chemoembolization (TACE) and Transcatheter Arterial Pegylated Interferon Embolization (TAIE) for Hepatocellular Carcinoma.
University of California, Los Angeles - Recruiting 18 years to 64 years. - Increasing Hepatitis B Screening Among Korean Church Attendees (Component Project) Program Project Title: Liver Cancer Control Interventions for Asian Americans.
Educational Small Group Session; Educational small group session
Charite University, Berlin, Germany - Recruiting 18 years or older. - Open One-Arm Therapy Optimizing Trial on Regional Chemotherapy of the Liver Through an Interventionally Implanted A.Hepatica Port System in Patients With Liver Metastases or Primary Liver Neoplasms..
interventionally implanted hepatic arterial port catheter